Novartis CEO Vas Narasimhan lines up his late-stage blockbuster contenders — mixing old favorites and add-ons
Every Big Pharma company is judged by its late-stage pipeline and the number of prospective blockbusters in play. Novartis CEO Vas Narasimhan is giving his pivotal strategy top marks today as the giant player reviews its development game plan in the wake of a couple of key setbacks.
Adding it all up, Novartis is using its R&D review to highlight a tally of 26 blockbusters in the pipeline, 13 projects in what is now grouped into cell, gene and radioligand work — adding radiopharmaceuticals to the group — while aiming for 60 “major” regulatory submissions from 2019-2022. And it’s already lining up promised approvals for next year, betting that they can shoot for key regulatory OKs based on the data in hand.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.